The evidence is solid but not definitive, as the conclusions rely on the absence of changes in spatial breadth and would benefit from clearer statistical justification and a more cautious ...
Recent decades have witnessed rapid advancements in high-intensity laser technology. The combination of laser irradiation and ...
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week ...
Gline laid out a catalyst-rich 2026, stating, "The Phase IIb data for mostly is expected firmly in the second half of this year. We now know that because the study is fully enrolled, obviously. Same ...
GRAND FALLS-WINDSOR, Newfoundland and Labrador, Jan. 27, 2026 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) ("First Atlantic" or the "Company") is pleased to ...
A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase modulators” was published by researchers at Nanyang Technological University, ...
Unfortunately, the Detroit Tigers were not one of the 12 teams that were taking players in the major league phase of the Rule 5 Draft. Instead, they saw their No. 30 prospect, RJ Petit, get stolen ...
Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase 2 multiple myeloma trial, paving the way for smoother and more effective ...
ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results